Improving the lives of people suffering from mental illness and substance use disorders

Developing improved pharmaceuticals based on innovative drug delivery technologies

Providing evidence-based digital therapies to improve treatment outcomes

What we do



Commercializing and developing pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

Today our thoughts go to people around the world who are suffering from MENTAL ILLNESS.

At Orexo we EMPOWER these people. Their well-being is at the HEART of what we do and understanding their needs and challenges are key for us.

In our blog we shed LIGHT on them and giving HOPE there is a road to recovery.

Key News

OCTOBER 22, 2021
Invitation to presentation of the Q3 Interim Report, November 3 at 1 pm CET

OCTOBER 18, 2021
MODIA™ paper published in the JMIR Mental Health

AUGUST 30, 2021
Synthetic opioids drive record-high surge in fatal overdoses

Orexo Social

22 October 2021

Last week we attended the Behavioral Healthcare’s Annual Meeting in Washington DC. Great to connect with so many be…

20 October 2021

Look forward to commence a partnership with @just_miine_ which will allow access to our clinically proven digital t…

19 October 2021

We are so proud to have Dennis Urbaniak,EVP Digital Therapeutics, in a nice piece of article @Forbes where he gives…

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

News Flow

Regulatory Press Releases

Financial Snapshot

Group net revenues

585 MSEK



-76 MSEK


US Pharma segment EBIT

295 MSEK


Cash position

680 MSEK

Q2 2021

1 Last Twelve Months, Q320-Q221, for more information about financial development Link